Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

0.4108 +0.0563 (+15.88%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,364,518
Open 0.3700
Bid (Size) 0.4070 (100)
Ask (Size) 0.4200 (35)
Prev. Close 0.3545
Today's Range 0.3400 - 0.4385
52wk Range 0.2600 - 3.163
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-56.30%
-56.30%
1 Month
-49.25%
-49.25%
3 Month
-56.99%
-56.99%
6 Month
-76.92%
-76.92%
1 Year
-79.56%
-79.56%

More News

Read More
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
Via FinancialNewsMedia
Topics Cannabis Death
Exposures Cannabis Death
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
From FN Media Group LLC
Via GlobeNewswire
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Set for Continued Expansion in 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
From bioAffinity Technologies, Inc.
Via Business Wire
Are Pharma Stocks Harmful To Your Financial Health ?
Via Talk Markets
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
From bioAffinity Technologies, Inc.
Via Business Wire
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
From bioAffinity Technologies, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.